Cyclin E as molecular marker in the management of breast cancer: A review

Analytical and Quantitative Cytology and Histology

Volumn 28, Issue 2, 2006, Pages 111-114

  Lopez Beltran, Antonio ^a   MacLennan, Gregory T ^b   Montironi, Rodolfo ^c  

^a Universidad de Cordoba   (Spain)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Breast cancer; Cyclin E; Molecular markers; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; ELASTASE; ELASTASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLAVOPIRIDOL; MOLECULAR MARKER; PEPTIDE FRAGMENT; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CANCER THERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; GENE AMPLIFICATION; HUMAN; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONTENT; PROTEIN PROCESSING; REVIEW;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; DISEASE PROGRESSION; FEMALE; HUMANS; PANCREATIC ELASTASE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 33645838628     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Hunt KK, Keyomarsi K: Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol 2005;15:319-326
2. Planas-Silva MD, Weinberg RA: Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997;17:4059-4069
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
4. Akli S, Keyomarsi K: Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2003;2:S38-S47
5. Akli S, Keyomarsi K: Low-molecular-weight cyclin E: The missing link between biology and clinical outcome. Breast Cancer Res 2004;6:188-191
6. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K: Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198-3208
7. Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP: Deregulation of cyclin E in breast cancer. Oncogene 1995;11:941-950
8. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS: Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-1575
9. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR, Roberts JM: Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992;257:1689-1694
10. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG: Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 2003;22:4898-4904
11. Spruck CH, Won KA, Reed SI: Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300
12. Honrado E, Benitez J, Palacios J: The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mod Pathol 2005;18:1305-1320
13. Sgambato A, Han EK, Zhou P, Schieren I, Weinstein IB: Overexpression of cyclin E in the HC11 mouse mammary epithelial cell line is associated with growth inhibition and increased expression of p27(Kip1). Cancer Res 1996;56:1389-1399
14. Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville EA: Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: Correlation with decreased H1 kinase activity. Biochem Pharmacol 1993;46:1831-1840
15. Smith ML, Seo YR: Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations. Anticancer Res 2000;20:2537-2539
16. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-2978